Congenica’s Sapientia clinical genome analysis software platform will be used by China-based UniteGen to do whole genome sequencing (WGS) processing and analysis as part of China’s “100K Wellness Pioneer Project,” hosted by Beijing 4P Health Research Institute.

The China-wide initiative aims to analyse and understand the genomes, metabolomes, proteomes, and clinical symptoms of 100,000 Chinese individuals with the goal of improving disease prevention and promoting overall healthcare management.

It was announced during the Fourth 301 Health Forum 2017 and Sixth National Checkup Centre Director Summit and PLA Health Management Committee Annual Conference, in May, organised by PLA General Hospital, Chinese Health Management Association and PLA Health Management Professional Committee.

Use of Sapientia is part of a strategic commercial agreement with Congenica to support UniteGen’s operations in China, announced earlier this year. Under the agreement, UniteGen will be processing and analysing all of the sequencing data generated during the project.

Weike Mo, founder and CEO of UniteGen, commented: “Partnering with Congenica, a highly regarded global leader for genomic data analysis and clinical interpretation, is a significant milestone for UniteGen. Sapientia incorporates all the features needed by Chinese healthcare practitioners to integrate genetic testing into clinical decisions. The automated reporting software solves a critical bottleneck for the genetic testing industry in China.”

Shikha O’Brien, Chief Business Officer at Congenica, said: “Genomic technology will be central to the next generation healthcare system that is evolving rapidly in China and we are delighted to be working with UniteGen and the “100K Wellness Pioneer Project,” both at the forefront of that change and committed to the benefits it will bring to patients.”

China’s “100K Wellness Pioneer Project” is the second major national genomics project where Sapientia has played a key role. Genomics England has been using Sapientia during the past 2 years as the WGS Clinical Interpretation platform for its 100K Genomes project, which aims to sequence and analyze the genomes of NHS patients with rare diseases as well as their families, and patients with cancer.

WGS analysis enables rapid diagnosis of rare disease, ensuring that an appropriate course of management and treatment can be administered to patients in as little as a few days.